Skip to main content

Advertisement

SpringerLink
Log in

High risk of occult hepatitis B virus infection in leukemia patients from China

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

In this study, we assessed the prevalence of overt and occult hepatitis B virus (HBV) infection among leukemia patients. Among 256 leukemia patients and 377 fracture patients (control group), we found that the hepatitis B surface-antigen-positive rate was greater in leukemia patients than in the controls (odds ratio, 2.08; p = 0.01). Moreover, the prevalence of occult HBV infection was higher in leukemia patients than in the controls (10.5 % vs. 2.9 %; odds ratio, 3.92; p < 0.001). The HBV genotype distribution differed significantly between the leukemia and chronic hepatitis B or control groups (p < 0.001 and 0.01, respectively); specifically, genotype C was primarily observed in occult HBV infection patients with leukemia. The stop codon mutation rate or amino acid substitutions in the major hydrophilic region did not differ between the groups. Thus, the prevalence of occult hepatitis B is higher in leukemia patients, and the HBV genotype distribution differs between patients with leukemia and chronic hepatitis B virus infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Li JH, Guo H, Gao XH, Chen HD (2015) Multiple skin ulcers from malignant syphilis. Lancet 386:1564. doi:10.1016/S0140-6736(15)60157-X

    Article  PubMed  Google Scholar 

  2. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6:531–561. doi:10.1007/s12072-012-9365-4

    Article  PubMed  Google Scholar 

  3. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185. doi:10.1016/j.jhep.2012.02.010

    Article  Google Scholar 

  4. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661–662. doi:10.1002/hep.23190

    Article  PubMed  Google Scholar 

  5. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652–657. doi:10.1016/j.jhep.2008.07.014

    Article  PubMed  Google Scholar 

  6. Schmeltzer P, Sherman KE (2010) Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 55:3328–3335. doi:10.1007/s10620-010-1413-0

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hu KQ (2002) Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9:243–257

    Article  PubMed  Google Scholar 

  8. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102:1930

    Article  CAS  PubMed  Google Scholar 

  9. Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, Spengler U (1998) Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 29:306–309

    Article  CAS  PubMed  Google Scholar 

  10. Kidd-Ljunggren K, Simonsen O (1999) Reappearance of hepatitis B 10 years after kidney transplantation. N Engl J Med 341:127–128

    Article  CAS  PubMed  Google Scholar 

  11. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M (1988) Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 69(Pt 10):2575–2583

    Article  CAS  PubMed  Google Scholar 

  12. Shi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, Higgins DG (2013) Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. Infect Genet Evol 16:355–361. doi:10.1016/j.meegid.2013.03.021

    Article  CAS  PubMed  Google Scholar 

  13. Kao JH, Chen PJ, Lai MY, Chen DS (2004) Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 72:363–369

    Article  CAS  PubMed  Google Scholar 

  14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107

    Article  PubMed  Google Scholar 

  15. Chen WQ, Shan BE, Zheng RS, Lin GZ, Chen JZ, Chen JG, He YT (2012) Analysis of incidence and mortality of leukemia in registration areas of China from 2003 to 2007. Tumor 32:376–377

    Google Scholar 

  16. Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS (2010) Cancer trends in Taiwan. Jpn J Clin Oncol 40:897–904. doi:10.1093/jjco/hyq057

    Article  PubMed  Google Scholar 

  17. Power JP, El Chaar M, Temple J, Thomas M, Spillane D, Candotti D, Allain JP (2010) HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus. J Hepatol 53:780–787. doi:10.1016/j.jhep.2010.04.034

    Article  CAS  PubMed  Google Scholar 

  18. Marinone C, Mestriner M (2011) HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 43(Suppl 1):S49–S56. doi:10.1016/S1590-8658(10)60692-5

    Article  CAS  PubMed  Google Scholar 

  19. Han JW, Yang H, Lee HL, Bae SH, Choi JY, Lee JW, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Yoon SK (2016) Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatol Res 46(7):657–668. doi:10.1111/hepr.12603

    Article  CAS  PubMed  Google Scholar 

  20. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T (2014) Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312:2521–2530. doi:10.1001/jama.2014.15704

    Article  PubMed  Google Scholar 

  21. Hsiao LT, Chiou TJ, Gau JP, Yang CF, Yu YB, Liu CY, Liu JH, Chen PM, Tzeng CH, Chan YJ, Yang MH, Huang YH (2015) Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-hodgkin lymphoma patients: a large cohort retrospective study. Medicine (Baltimore) 94:e1321. doi:10.1097/MD.0000000000001321

    Article  CAS  Google Scholar 

  22. Zhang Z, Zhang L, Dai Y, Jin L, Sun B, Su Q, Li X (2015) Occult hepatitis B virus infection among people with a family history of chronic hepatitis B virus infection. J Med Virol 87:1890–1898. doi:10.1002/jmv.24245

    Article  CAS  PubMed  Google Scholar 

  23. Zhang ZH, Zhang L, Dai Y, Zhang YF, Li J, Li X (2016) Occult hepatitis B virus infection: Influence of S protein variants. Virol J 13(1):10. doi:10.1186/s12985-016-0464-z

    Article  PubMed  PubMed Central  Google Scholar 

  24. Zhang ZH, Zhang L, Lu MJ, Yang DL, Li X (2009) Establishment of reference sequences of hepatitis B virus genotype B and C in China. Zhonghua Gan Zang Bing Za Zhi 17:891–895

    CAS  PubMed  Google Scholar 

  25. Zhang Z, Xia J, Sun B, Dai Y, Li X, Schlaak JF, Lu M (2015) In vitro and in vivo replication of a chemically synthesized consensus genome of hepatitis B virus genotype B. J Virol Methods 213:57–64. doi:10.1016/j.jviromet.2014.11.007

    Article  CAS  PubMed  Google Scholar 

  26. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731–2739. doi:10.1093/molbev/msr121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhang ZH, Wu CC, Chen XW, Li X, Li J, Lu MJ (2016) Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol 22:126–144. doi:10.3748/wjg.v22.i1.126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wang H, Fang M, Gu X, Ji Q, Li D, Cheng SQ, Shen F, Gao CF (2014) The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China. PLoS One 9:e107162. doi:10.1371/journal.pone.0107162

    Article  PubMed  PubMed Central  Google Scholar 

  29. Wong DK, Fung J, Lee CK, Seto WK, Leung J, Huang FY, Lin CK, Lai CL, Yuen MF (2015) Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. Clin Microbiol Infect 22(3):290.e1–290.e3. doi:10.1016/j.cmi.2015.10.036

    Article  Google Scholar 

  30. Paganelli M, Stephenne X, Sokal EM (2012) Chronic hepatitis B in children and adolescents. J Hepatol 57:885–896. doi:10.1016/j.jhep.2012.03.036

    Article  PubMed  Google Scholar 

  31. Luo Z, Li L, Ruan B (2012) Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 16:e82–e88. doi:10.1016/j.ijid.2011.10.009

    Article  PubMed  Google Scholar 

  32. Zhang ZH, Li L, Zhao XP, Glebe D, Bremer CM, Zhang ZM, Tian YJ, Wang BJ, Yang Y, Gerlich W, Roggendorf M, Li X, Lu MJ, Yang DL (2011) Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without virus clearance. J Viral Hepat 18:424–433. doi:10.1111/j.1365-2893.2010.01322.x

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the staff members of the Department of Blood Diseases and Department of Orthopedics, First Affiliated Hospital, Anhui Medical University, for their help with sample collection. This study was funded by the Anhui Provincial Natural Science Foundation (1608085MH162) and Specialized Research Fund for the Doctoral Program of Higher Education of China (20093420120005). The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, The First Affiliated Hospital, Anhui Medical University, Jixi Road 218, 230022, Hefei, China

    Zhenhua Zhang, Yafei Zhang, Nan Xu & Xu Li

  2. School of Pharmacy, Anhui Medical University, Hefei, 230022, China

    Zhenhua Zhang, Cheng Huang & Jun Li

Authors
  1. Zhenhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yafei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhenhua Zhang or Jun Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Z., Zhang, Y., Xu, N. et al. High risk of occult hepatitis B virus infection in leukemia patients from China. Arch Virol 162, 349–357 (2017). https://doi.org/10.1007/s00705-016-3111-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-016-3111-5

Keywords

Search

Navigation